No Data
No Data
KalVista Pharmaceuticals Up Over 19%, on Pace for Largest Percent Increase Since February 2021 -- Data Talk
KalVista Pharmaceuticals Initiated at Buy by Jones Trading
JonesTrading Initiates KalVista Pharmaceuticals(KALV.US) With Buy Rating, Announces Target Price $35
Buy Rating Affirmed for KalVista Pharmaceuticals Amid Strong Phase 3 Data and Market Potential
Express News | Kalvista Pharmaceuticals Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $35
KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference